Can-Fite Biopharma Ltd.

Dermatology and Inflammatory Skin Disease

Can-Fite Biopharma Ltd. funds clinical research in plaque psoriasis, with a focus on moderate-to-severe disease and treatment response in chronic immune-mediated skin inflammation.

  • PASI response
  • Static Physician’s Global Assessment
  • Safety evaluation

Its dermatology portfolio reflects interest in clinical endpoints that measure improvement in skin clearance and overall disease severity.

Hepatology and Metabolic Liver Disease

The sponsor also supports research in non-alcoholic steatohepatitis with fibrosis, targeting a progressive liver condition linked to metabolic dysfunction and chronic hepatic inflammation.

  • NAFLD activity score
  • NASH clinical outcomes
  • Liver fibrosis

This area centers on liver disease activity and structural damage in patients affected by advanced fatty liver disease.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effects and Safety of Piclidenoson for Patients with Moderate-to-Severe Plaque Psoriasis

    Recruiting

    3 1
    Investigated drugs:
    Bulgaria Greece Poland
  • Study of Namodenoson Treatment in Patients with Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

    Recruiting

    2 1
    Investigated drugs:
    Bulgaria Poland Romania